 11. Subject has impaired liver function e.g., alanine aminotransferase ALT 3 times the upper limit of normal ULN or bilirubin 3 times ULN, known active hepatic disease e.g., hepatitis, or evidence of clinically significant liver disease or other condition affecting the liver that may suggest the potential for an increased susceptibility to hepatic toxicity with oral diclofenac exposure. 